PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11288046-0	2001	Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.	Bezafibrate	11-22	insulin	Homo sapiens	26-33	
11288046-1	2001	The aim of the present study was to investigate the effect of bezafibrate on insulin sensitivity and insulin secretion in 30 non-obese Japanese type 2 diabetic patients with hypertriglyceridemia (serum triglycerides > 150 mg/dL).	Bezafibrate	62-73	insulin	Homo sapiens	77-84	
10403804-6	1999	Since UCP-3 mRNA levels are reduced in skeletal muscle of diabetic patients, this effect may be involved in the improvement of insulin sensitivity caused by bezafibrate in NIDDM.	Bezafibrate	157-168	insulin	Homo sapiens	127-134	
10868845-0	2000	Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients.	Bezafibrate	10-21	insulin	Homo sapiens	25-32	
1458771-0	1992	Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia.	Bezafibrate	11-22	insulin	Homo sapiens	26-33	
9381994-0	1997	Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.	Bezafibrate	14-25	insulin	Homo sapiens	64-71	
7851275-4	1994	Administration of bezafibrate at 400 mg/day for 4 weeks to the IGT patients with hypertriglyceridemia resulted in an improvement of the plasma glucose level and insulin response to 75 g oral glucose loading associated with a concomitant decrease in non-esterified fatty acids.	Bezafibrate	18-29	insulin	Homo sapiens	161-168	
7851275-5	1994	The ratio of the level of serum C-peptide to that of insulin after a 75 g oral glucose tolerance test (OGTT) was augmented after 4 weeks of bezafibrate administration.	Bezafibrate	140-151	insulin	Homo sapiens	53-60	
33525941-4	2021	Three of them (tazarotenic acid, bezafibrate, and efaproxiral) affect insulin secretion in pancreatic INS-1 832/13 beta-cells with EC50 in the nanomolar concentration (5.73, 14.2, and 13.5 nM, respectively).	Bezafibrate	33-44	insulin	Homo sapiens	70-77	
2653325-0	1989	Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.	Bezafibrate	11-22	insulin	Homo sapiens	26-33	
23150952-16	2012	The principal differences between bezafibrate and other fibrates are related to effects on glucose level and insulin resistance.	Bezafibrate	34-45	insulin	Homo sapiens	109-116	
23254592-8	2013	In conclusion, bezafibrate improved lipid metabolism and insulin sensitivity but did not affect office, home or ambulatory BP in hypertensive patients with dyslipidemia.	Bezafibrate	15-26	insulin	Homo sapiens	57-64	
25360162-15	2014	Therefore, bezafibrate could be used to treat insulin resistance in patients with type 2 diabetes mellitus and dyslipidemia.	Bezafibrate	11-22	insulin	Homo sapiens	46-53	
12733699-9	2003	In conclusion, an improvement of hyperlipidemia by bezafibrate may be attributed to reduction of blood pressure and amelioration of insulin sensitivity.	Bezafibrate	51-62	insulin	Homo sapiens	132-139	
19131462-8	2009	Post hoc analysis of the effect of bezafibrate on progression of preexisting diabetes also showed a lower hazard for progression to use of antidiabetic medication (0.54 [0.38-0.76]) or progression to use of insulin (0.78 [0.55-1.10]).	Bezafibrate	35-46	insulin	Homo sapiens	207-214	
12733699-1	2003	We examined cellular membrane fatty acid composition and insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate, a lipid-lowering drug, could improve elevated blood pressure and insulin sensitivity in these subjects by ameliorating cellular membrane fatty acid composition.	Bezafibrate	167-178	insulin	Homo sapiens	245-252	
16606809-0	2006	Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.	Bezafibrate	93-104	insulin	Homo sapiens	30-37	
12754275-11	2003	Bezafibrate-induced diminished insulin resistance is associated with a reduction of CET and PLTP activity.	Bezafibrate	0-11	insulin	Homo sapiens	31-38	
12472919-0	2002	Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance.	Bezafibrate	0-11	insulin	Homo sapiens	108-115	
12472919-7	2002	This effect could result from the increased glucose uptake observed and a decrease in insulin resistance secondary to the lowered triglyceride levels by bezafibrate.	Bezafibrate	153-164	insulin	Homo sapiens	86-93	
11893366-0	2002	Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.	Bezafibrate	108-119	insulin	Homo sapiens	33-40